Treatment of hepatitis C in elderly patients: Challenge for the future or present reality?

Liver International

Volumn 30, Issue 4, 2010, Pages 493-495

  Grange, Jean Didier ^a   Amiot, Xavier ^a  

^a HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; PEGINTERFERON; RIBAVIRIN; TARIBAVIRIN;

AGED; ALCOHOL CONSUMPTION; ANEMIA; ANTIVIRAL THERAPY; CYTOPENIA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG TOLERABILITY; EDITORIAL; ELDERLY CARE; GENOTYPE; GERIATRIC PATIENT; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; LIFE EXPECTANCY; LIVER BIOPSY; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; MENTAL DISEASE; RISK BENEFIT ANALYSIS; RISK FACTOR; SURVIVAL; TREATMENT DURATION; VIRUS LOAD;

AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; GERIATRIC ASSESSMENT; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 77950603652     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02209.x     Document Type: Editorial

References (20)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009, 29((Suppl. 1)):74-81.
2. Mostafa A, Taylor SM, El-Daly M. Is the hepatitis C virus epidemic over in Egypt ? Incidence and risk factors of new hepatitis C virus infections. Liver Int 2010, 30:560-566.
3. Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat 2007, 14:107-115.
4. Mariano A, Scalia Tomba G, Tosti ME, Spada E, Mele A. Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy. Scand J Infect Dis 2009, 41:689-699.
5. Mindikoglu AL, Miller RR. Hepatitis C in the elderly: epidemiology, natural history, and treatment. Clin Gastroenterol Hepatol 2009, 7:128-134.
6. Nudo CG, Wong P, Hilzenrat N, Deschenes M. Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C. Can J Gastroenterol 2006, 20:589-592.
7. Honda T, Katano Y, Shimizu J. Efficacy of peginterferon-α-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C. Liver Int 2010, 30:527-537.
8. Sezaki H, Suzuki F, Kawamura Y. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci 2009, 54:1317-1324.
9. Poynard T, Ratziu V, Charlotte F. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001, 34:730-739.
10. Pradat P, Voirin N, Tillmann HL, Chevallier M, Trepo C. Progression to cirrhosis in hepatitis C patients: an age-dependent process. Liver Int 2007, 27:335-339.
11. Ratziu V, Munteanu M, Charlotte F, Bonyhay L, Poynard T. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 2003, 39:1049-1055.
12. Di Martino V, Lebray P, Myers RP. Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology 2004, 40:1426-1433.
13. Yoshida H, Shiratori Y, Moriyama M. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med 1999, 131:174-181.
14. Ikeda K, Saitoh S, Koida I. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993, 18:47-53.
15. Degos F, Christidis C, Ganne-Carrie N. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000, 47:131-136.
16. Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 2002, 62((Suppl. 1)):8-17.
17. Ikeda K, Arase Y, Kawamura Y. Necessities of interferon therapy in elderly patients with chronic hepatitis C. Am J Med 2009, 122:479-486.
18. Tsui JI, Currie S, Shen H. Treatment eligibility and outcomes in elderly patients with chronic hepatitis C: results from the VA HCV-001 Study. Dig Dis Sci 2008, 53:809-814.
19. Benhamou Y, Afdhal NH, Nelson DR. A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naive patients with chronic hepatitis C: ViSER1 results. Hepatology 2009, 50:717-726.
20. Imai Y, Tamura S, Tanaka H. Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders. J Viral Hepat 2010, 17:185-191.